NDAINJECTIONINJECTABLE
Approved
Nov 2022
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20
Data completeness
7/8 — Comprehensive
DOCETAXEL (docetaxel) by Viatris (2) is functions. Approved for breast cancer, non-small cell lung cancer, prostate cancer and 1 more indications. First approved in 2022.
Drug data last refreshed 23h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Docetaxel is a taxane chemotherapy agent approved for treatment of 18 solid tumor indications including breast, lung, prostate, and gastric cancers. It works by binding to free tubulin and promoting stable microtubule assembly while inhibiting disassembly, thereby blocking mitosis and halting cancer cell division. The drug is administered intravenously and represents a foundational cytotoxic therapy in oncology.
$6KPart D
Peak9.9 years to LOEThe product is at peak commercial maturity with very low Medicare Part D spending, indicating limited growth potential and likely a small, maintenance-focused brand team.
Mechanism of Action
functions. Docetaxel binds to free tubulin and promotes the assembly of tubulin into stable microtubules while simultaneously inhibiting their disassembly. This leads to the production of microtubule bundles without normal function and to the stabilization of microtubules, which results in the…
Indications (4)
Worked on DOCETAXEL at Viatris (2)? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.